CUBT (Curative Biotechnology) Total Liabilities: $20.04 Mil (As of Mar. 2023)


What is Curative Biotechnology Total Liabilities?

Curative Biotechnology CUBT +19.71% Total Liabilities is $20.04 Mil as of Mar. 2023.

Curative Biotechnology's Total Liabilities for the quarter that ended in Mar. 2023 was $20.04 Mil.

Curative Biotechnology's quarterly Total Liabilities increased from Sep. 2022 ($21.13 Mil) to Dec. 2022 ($22.62 Mil) but then declined from Dec. 2022 ($22.62 Mil) to Mar. 2023 ($20.04 Mil).

Curative Biotechnology's annual Total Liabilities increased from Dec. 2020 ($6.80 Mil) to Dec. 2021 ($18.77 Mil) and increased from Dec. 2021 ($18.77 Mil) to Dec. 2022 ($22.62 Mil).

Curative Biotechnology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology Total Liabilities Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial 0.73 0.40 6.80 18.77 22.62

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.89 20.01 21.13 22.62 20.04

Curative Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Curative Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.487+(0+18.132
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=22.62

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=2.089--20.53
=22.62

Curative Biotechnology's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.332+(0+14.712
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=20.04

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=2.132--17.912
=20.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $20.04 Mil mean?
Curative Biotechnology (CUBT) has a Total Liabilities of $20.04 Mil as of Mar. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Curative Biotechnology and its competitors.
Is Curative Biotechnology's Total Liabilities too high?
Curative Biotechnology's current Total Liabilities is $20.04 Mil.
How does Curative Biotechnology's Total Liabilities compare to ORGS and SNSE?
Curative Biotechnology's Total Liabilities of $20.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Curative Biotechnology and its competitors. Curative Biotechnology's current Total Liabilities is $20.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current Total Liabilities of $20.04 Mil. The current Total Liabilities is $20.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current Total Liabilities is $20.04 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.